Pembrolizumab‐induced interstitial lung disease following thoracic surgery in a patient with non‐small cell lung cancer

The safety of treatment with immune‐checkpoint inhibitors prior to thoracic surgery in patients with non‐small cell lung cancer (NSCLC) remains unclear. Here, we describe the case of a 62‐year‐old woman with NSCLC with programmed death ligand 1 expression on 85% of tumor cells. The patient was initi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Thorac Cancer
Main Authors: Fujita, Tetsuo, Hayama, Nami, Kuroki, Tsuguko, Shiraishi, Yuka, Amano, Hiroyuki, Nakamura, Makoto, Hirano, Satoshi, Aramaki, Nao, Ichinose, Shuji, Shimizu, Shinichiro, Tabeta, Hiroshi, Nakamura, Sukeyuki
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons Australia, Ltd 2019
Assuntos:
Case Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6825914/
https://ncbi.nlm.nih.gov/pubmed/31512401
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13194
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados